Project Grant R33CA302632
Award Date 9/17/25
Completion Date 8/31/28
Dollars Obligated $293K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (NCI), under the Federal Assistance Listings program CFDA 93.395 Cancer Treatment Research, provides $406,500.00 to support the development of a novel, low-cost, single-use trans-nasal cryotherapy device for esophageal cancer treatment in low-resource settings. The project aims to design and validate a functional prototype of this first-of-its-kind device, which would enable unsedated cryoablation procedures to be administered through...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $273,388 to Histone Therapeutics, a woman-owned small business, aims to epigenetically modify natural killer (NK) cells to enhance their ability to detect and kill cancer cells. The goal is to develop a broad-spectrum NK cell therapy that can be used in combination with current cancer treatments to improve effectiveness without increasing side effects. The project will assess...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $3,182,665 to The Washington University to investigate how natural killer (NK) cells can subvert the effectiveness of immune checkpoint therapy for cancer treatment. The key objectives are to: 1) elucidate the mechanisms by which NK cells constrain the efficacy of immune checkpoint therapy, 2) evaluate the contribution of the NKG2D receptor in this process, and 3) translate the findings...
- The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research Federal Grant Program (CFDA 93.394), awarded a $399,444 Project Grant to Cancure LLC (Canzx Biotherapeutics) on August 1, 2025. The funding will support a feasibility study of a novel agent that aims to stimulate NK (natural killer) and CD8 T cells for potential use in treating solid tumors. The study seeks to address challenges with persistence and sustained function of these cell-based therapies in the solid...
- The Regents of the University of Minnesota received a $299,992 Project Grant award from the National Science Foundation to support the development of next-generation cryopreservation media for natural killer cells under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The two-year project period runs from May 1, 2021 through April 30, 2023. The NSF Technology, Innovation, and Partnerships program seeks to advance science and engineering research and innovation leading to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,253,869 to Celdara Medical, LLC to develop CM-HZ01, a novel non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The funding supports advancing CM-HZ01 to the Investigational New Drug (IND) application stage, with the goal of providing a best-in-class immunotherapy for patients with limited effective treatment options for this deadly form of skin cancer. The project...
- This federal Project Grant award of $1,340,987 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to revolutionize chimeric antigen receptor (CAR) T-cell therapy by developing a novel CAR-enhancer platform. The platform seeks to augment the functionality and longevity of CAR T-cells, addressing the key challenge of limited durability of response in patients. The specific objectives of this 24-month project are to: 1) Optimize dosing and timing for administering the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $192,564.00 to The Ohio State University to develop a natural killer (NK) cell-based immunotherapy for the treatment of pediatric solid tumors. The key objectives are to explore a novel monomeric chimeric antigen receptor (CAR) design to optimize NK cell signaling and function, and to define a donor selection algorithm for CAR NK cell products. The award aims to leverage the...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $350,000 in funding to Cisterna Biologics, Inc. to develop a novel mRNA production and purification process. The key objectives are to: Optimize psychrophilic (cold-adapted) RNA polymerases and synthetic promoters to minimize contaminants in mRNA synthesis, improving safety and efficacy for therapeutic use. Implement...
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...